Medscape www.medscape.com

References for:
Core Binding Factor (CBF) Primary Acute Myeloid Leukemia: Biology and Clinical Implications

[Medscape General Medicine 2(2), 2000. © 2000 Medscape]

  1. Bloomfield CD, Goldman A, Hossfeld D, et al. Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet. 1984;11:332-350.
  2. Mrózek K, Bloomfield CD. Chromosome aberrations in de novo acute myeloid leukemia in adults: clinical implications. Rev Clin Exp Hematol. 1998;5:44-67.
  3. Look AT. Oncogenic transcription factors in human acute leukemia. Science. 1997;278:1059-1064.
  4. Caligiuri MA, Strout MP, Gilliland DG. Molecular biology of acute myeloid leukemia. Semin Oncol. 1997;24:32-44.
  5. Ito Y. Structural alterations in the transcription factor PEBP2/CBF linked to four different types of leukemia. J Cancer Res Clin Oncol. 1996;122:266-274.
  6. Mrózek K, Heinonen K, de la Chapelle A, et al. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17-31.
  7. van der Reijden BA, van Ommen GJ, Hagemeijer A, et al. Acute myelogenous leukemia: a disorder of gene splicing? Leukemia. 1996;10:204-206.
  8. van der Reijden BA, Bloomfield CD, Touw IP, et al. Acute leukemias with structurally altered core binding factor subunits (t(8;21), inv(16), t(12;21)), 27-28 June 1997, Rotterdam, The Netherlands. Leukemia. 1997;11:2217-2219.
  9. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBFbeta/PEBP2beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261:1041-1044.
  10. Okuda T, van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
  11. Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet. 1997;15:303-306.
  12. Castilla LH, Wijmenga C, Wang Q, et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell. 1996;87:687-696.
  13. Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 1996;87:697-708.
  14. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992;80:1825-1831.
  15. Nucifora G, Birn DJ, Erickson P, et al. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood. 1993;81:883-888.
  16. Nisson PE, Watkins PC, Sacchi N. Transcriptionally active chimeric gene derived from the fusion of the AML gene and a novel gene on chromosome 8 in t(8;21) leukemic cells. Cancer Genet Cytogenet. 1993;66:81-88.
  17. Miyoshi H, Kozu T, Shimizu K, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 1993;12:2715-2712.
  18. Erickson PF, Dessev G, Lasher RS, et al. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood. 1996;88:1813-1823.
  19. Hetherington CJ, Yergeau DA, Tenen DG, et al. Inducible AML1-ETO expression in transgenic mice. Blood. 1997;90(Suppl 1):59a. Abstract.
  20. Sakakura C, Yamaguchi-Iwai Y, Satake M, et al. Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO) specific antisense oligonucleotide. Proc Natl Acad Sci USA. 1994;91:11723-11727.
  21. Nucifora G, Begy CR, Kobayashi H, et al. Consistent intergeneic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in 93;21)(q26;q22) translocations. Proc Natl Acad Sci USA. 1994;91:4004-4008.
  22. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia. 1997;11:2022-2031.
  23. Tanaka T, Mitani K, Kurokawa M, et al. Dual function of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemia. Mol Cell Biol. 1995;15:2383-2392.
  24. Kurokawa M, Ogawa S, Tanaka T, et al. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on RAT1 fibroblasts with dependence on the Evi-1 sequence. Oncogene. 1995;11:833-840.
  25. Liu PP, Hajra A, Wijmenga C, et al. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood. 1995;85:2289-2302.
  26. van der Reijden BA, Dauwerse JG, Wessels JW, et al. A gene for a myosin peptide is disrupted by the inv(16)(p13q22) in acute nonlymphocytic leukemia M4Eo. Blood. 1993;82:2948-2952.
  27. Claxton DF, Liu P, Hsu HB, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood. 1994;83:1750-1756.
  28. Hebert J, Cayuela JM, Daniel MT, et al. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Blood. 1994;84:2291-2296.
  29. Castilla L, Garret L, Adya N, et al. The fusion gene, Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nature Genet. 1999;23:144-146.
  30. Fischer K, Scholl C, Salat J, et al. Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. Blood. 1996;88:3962-3971.
  31. Dohner H, Stilgenbauer S, Fischer K, et al. Diagnosis and monitoring of chromosome aberrations in hematological malignancies by fluorescence in situ hybridization. Stem Cells. 1995;13:76-82.
  32. Marlton P, Claxton DF, Liu P, et al. Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis. Blood. 1995;85:772-779.
  33. Andrieu V, Radford-Weiss I, Troussard X, et al. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype. Br J Haematol. 1996;92:855-865.
  34. Langabeer SE, Walker H, Gale RE, et al. Frequency of CBFbeta/MYH11 fusion transcripts in patients entered into the UK MRC AML trials. Br J Haematol. 1997;96:736-739.
  35. Langabeer SE, Walker H, Rogers JR, et al. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. Br J Haematol. 1997;99:925-928.
  36. Langabeer SE, Grimwade D, Walker H, et al. A study to determine whether trisomy 8, deleted 9q and trisomy 22 are markers of cryptic rearrangements of PML/RAR___AML1/ETO, CBFB/MYH11 respectively in acute myeloid leukemia. Br J Haematol. 1998:338-340.
  37. Mitelman F. Catalog of Chromosome Aberrations in Cancer (ed 5). New York, Wiley-Liss; 1994.
  38. Fourth International Workshop on Chromosomes in Leukemia, 1982: Overview of association between chromosome pattern and cell morphology, age, sex, and race. Cancer Genet Cytogenet. 1984;11:265-274.
  39. Nakamura H, Kuriyama K, Sadamori N, et al. Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21). Leukemia. 1997;11:651-655.
  40. Arthur DC, Bloomfield CD. Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute non-lymphocytic leukemia: a new association. Blood. 1983;61:994.
  41. Le Beau MM, Larson RA, Bitter MA, et al. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia: a unique cytogenetic-clinicopathological association. N Engl J Med. 1983;309:630.
  42. de la Chapelle A, Lahtinen R. Chromosome 16 and bone-marrow eosinophilia [letter]. N Engl J Med. 1983;309:1394.
  43. Heim S, Mitelman F. Cancer Cytogenetics (ed 2). New York: Wiley-Liss; 1995.
  44. Grois N, Nowotny H, Tyl E, et al. Is trisomy 22 in acute myeloid leukemia a primary abnormality or only a secondary change associated with inversion 16? Cancer Genet Cytogenet. 1989;43:119-129.
  45. Costello R, Sainty D, Lecine P, et al. Detection of CBF_/MYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics. Leukemia. 1997;11:644-650.
  46. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia. 1995;9:1491-1498.
  47. Groupe Francais de Cytogenetique Hematologique. Acute myeloid leukemia with an 8;21 translocation. A report of 148 cases from the Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet. 1990;44:169-179.
  48. Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996;10:1288-1295.
  49. Mertens F, Johansson B, Mitelman F. Age- and gender-related heterogeneity of cancer chromosome aberrations. Cancer Genet Cytogenet. 1993;70:6-11.
  50. Haferlach T, Bennett JM, Loffler H, et al. Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. Leuk Lymph. 1996;23:227-234.
  51. Byrd JC, Weiss RB, Arthur DC, et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997;15:466-475.
  52. O'Brien S, Kantarjian HM, Keating M, et al. Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21. J Clin Oncol. 1989;7:1081-1086.
  53. Schoch C, Haase D, Haferlach T, et al. Secondary chromosome aberrations in acute myeloid leukemia with t(8;21)(q22;q22), inv(16)(p13q22) or t(15;17)(q22;q21) [abstract]. Blood. 1995;86:43a.
  54. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t98;210(q22;q22). Blood. 1997;90:1643-1650.
  55. Marlton P, Keating M, Kantarjian H, et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia. 1995;9:965-971.
  56. Campbell LJ, Challis J, Fok T, et al. Chromosome 16 abnormalities associated with myeloid malignancies. Genes Chromosomes Cancer. 1991;3:55-61.
  57. Tosi P, Visani G, Ottaviani E, et al. Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro. Eur J Haematol. 1998;60:161-165.
  58. Kuss BJ, Deeley RG, Cole SP, et al. The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Leuk Lymph. 1996;20:357-364.
  59. Skipper HE, Schaebel FM, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep. 1964;35:1-11.
  60. Wolff SN, Herzig RH, Fay JW, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long term follow-up and results. J Clin Oncol. 1989;7:1260-1267.
  61. Bloomfield CD, Herzig GP, Peterson BA, et al. Long-term survival of patients with acute myeloid leukemia. Updated results from two trials evaluating postinduction chemotherapy. Cancer. 1997;80(suppl 11):2186-2190.
  62. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896-903.
  63. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration following high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:1473-1479.
  64. Bloomfield CD, Shuma C, Regal L, et al. Long-term survival of patients with acute myeloid leukemia. A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer. 1997;80(suppl 11):2191-2198.
  65. Gale PR, Horowitz MM, Weiner RS, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplantation. 1995;16:203-208.
  66. Ferrant A, Labopin M, Frassoni F, et al: Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation study. Blood. 1997;90:2921-2938.
  67. Burnett AK, Wheatley K, Langabeer S, et al. Outcome of acute myeloid leukemias affecting core binding factor subunits: The UK MRC experience. Blood. 1997;90(suppl.1):390a. Abstract.
  68. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995;85:2632-2638.
  69. Lo Coco F, Diverio D, Avvisati G, et al. Prospective RT-PCR monitoring of minimal residual disease in acute promyelocytic leukemia (APL) patients enrolled in the multicentric GINEMA-AIEOP "AIDA" trial [abstract]. Blood. 1997;90(suppl1):390a.
  70. Slack JL: Recent advances in the biology and treatment of acute promylocytic leukemia. ASCO Educational Book Spring 1998:54-65.
  71. Downing JR, Head DR, Curcio-Brint AM, et al. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood. 1993;81:2860-2865.
  72. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 1993;82:712-715.
  73. Kusec R, Laczika K, Knobl P, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia. 1994;8:735-739.
  74. Saunders MJ, Tobal K, Yin JA. Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. Leukemia Res. 1994;18:891-895.
  75. Jurlander J, Caligiuri MA, Ruutu T, et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood. 1996; 88:2183-2191.
  76. Muto A, Mori S, Matsushita H, et al. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. Br J Haematol. 1996;95:85-94.
  77. Tobal K, Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21). Blood. 1996;88:3704-3709.
  78. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res. 1996;6:986-994.
  79. Marcucci G, Livak KJ, Bi WL, et al. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia. 1998;12:1482-1489.
  80. Marcucci G, Caligiuri MA, Bloomfield CD. Defining the "absence" of the CBF_/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: A call for definitions [letter]. Blood. 1997;90:5022-5024, 1997.
  81. Tobal K, Johnson PR, Saunders MJ, et al. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol. 1995;91:104-108.
  82. Costello R, Sainty D, Blaise D, et al. Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBF beta/MYH11-positive acute myeloblastic leukemia [letter]. Blood. 1997;89:2222-2223.
  83. Evans PA, Short MA, Jack AS, et al. Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML. Leukemia. 1997;11:364-369.
  84. Elmaagacli AH, Beelen DW, Kroll M, et al. Detection of CBFbeta/MYH11 fusion transcript in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplantation. 1998;21:159-166.
  85. Laczika K, Novak M, Hilgarth B, et al. Competitive CBFbeta/MYH11 reverse-transcription polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): A pilot study. J Clin Oncol. 1998;16:1519-1525.
  86. Schiffer CA, Lee EJ, Tomiyasu T, et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989;73:263-270.
  87. Fenaux P, Lai JL, Preudhomme C, et al. Is translocation (8;21) a "favorable" cytogenetic rearrangement in acute myeloid leukemia? Nouv Rev Fr Hematol. 1990;32:179-182.
  88. Tien HF, Wang CH, Lin MT, et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet. 1995;84:60-68.
  89. Marosi C, Koller U, Koller-Weber E, et al. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet Cytogenet. 1992;61:14-25.
  90. Joventino LP, Stock W, Lane NJ, et al. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. Leukemia. 1995;9:433-439.
  91. Bloomfield CD, for Cancer and Leukemia group B (CALGB). Clinical outcome of acute myeloid leukemia (AML) involving CBF [abstract]. Leukemia. 1997;11:2224.
  92. Billstrom R, Johansson B, Fioretos T, et al. Poor survival in t(8;21) (q22;q22)-associated acute myeloid leukaemia with leukocytosis. Eur J Haematol. 1997;59:47-52.
  93. Berger R, Bernheim A, Ochoa-Noguera ME, et al. Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: a study of 343 patients. Cancer Genet Cytogenet. 1987;28:293-299.
  94. Keating MJ, Smith TC, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia. 1988;2:403-412.
  95. Plantier I, Lai JL, Wattel E, et al. Inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up. Leuk Res. 1994;18:885-888.